AstraZeneca follows Merck’s pullback in Britain (AZN:NASDAQ)

Core Insights - AstraZeneca has paused plans for a £200 million (~$271 million) investment in its Cambridge research site, reflecting a reconsideration of investment options in Britain [2] Company Actions - The decision to halt the investment follows a similar move by Merck, indicating a trend among leading drugmakers to reassess their commitments in the UK [2]